Protocadherin Gamma C3 (PCDHGC3) Is Strongly Expressed in Glioblastoma and Its High Expression Is Associated with Longer Progression-Free Survival of Patients.
PCDHGC3
WNT signaling
astrocytoma
brain
expression
glioblastoma multiforme
glioma
mRNA
protein
recurrence
relapse
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
22 Jul 2022
22 Jul 2022
Historique:
received:
31
05
2022
revised:
11
07
2022
accepted:
20
07
2022
entrez:
28
7
2022
pubmed:
29
7
2022
medline:
30
7
2022
Statut:
epublish
Résumé
Protocadherins (PCDHs) belong to the cadherin superfamily and represent the largest subgroup of calcium-dependent adhesion molecules. In the genome, most PCDHs are arranged in three clusters,
Identifiants
pubmed: 35897674
pii: ijms23158101
doi: 10.3390/ijms23158101
pmc: PMC9330298
pii:
doi:
Substances chimiques
Cadherin Related Proteins
0
Cadherins
0
PCDHGC3 protein, human
0
Protocadherins
0
RNA, Messenger
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Oncol Lett. 2017 Sep;14(3):3357-3362
pubmed: 28927088
J Cereb Blood Flow Metab. 2017 Oct;37(10):3391-3400
pubmed: 28094605
Mol Cell Neurosci. 2005 Aug;29(4):603-16
pubmed: 15964765
Nat Rev Clin Oncol. 2021 Mar;18(3):170-186
pubmed: 33293629
Curr Opin Cell Biol. 2002 Oct;14(5):557-62
pubmed: 12231349
Acta Neuropathol. 2018 Nov;136(5):805-810
pubmed: 30259105
Cancer Res. 2008 Oct 15;68(20):8616-25
pubmed: 18922938
Genome Res. 2011 Jul;21(7):1017-27
pubmed: 21521786
Front Physiol. 2020 Nov 12;11:569881
pubmed: 33281613
Exp Cell Res. 2017 Sep 1;358(1):3-9
pubmed: 28268172
J Cereb Blood Flow Metab. 2018 Nov;38(11):1940-1953
pubmed: 29633884
Transl Stroke Res. 2019 Dec;10(6):672-683
pubmed: 30617994
Cell Adh Migr. 2015;9(3):214-26
pubmed: 25869446
Front Pharmacol. 2020 Nov 30;11:590144
pubmed: 33390965
Curr Opin Cell Biol. 2007 Oct;19(5):584-92
pubmed: 17936607
Cancers (Basel). 2020 Apr 27;12(5):
pubmed: 32349320
CA Cancer J Clin. 2020 Jul;70(4):299-312
pubmed: 32478924
Science. 2018 May 11;360(6389):660-663
pubmed: 29748285
J Neurooncol. 2020 Apr;147(2):297-307
pubmed: 32157552
J Mol Med (Berl). 2004 Oct;82(10):656-70
pubmed: 15316624
Fluids Barriers CNS. 2020 Apr 22;17(1):31
pubmed: 32321535
Sci Rep. 2016 Aug 17;6:31665
pubmed: 27530555
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
PLoS Genet. 2009 Nov;5(11):e1000745
pubmed: 19956686
J Clin Neurosci. 2012 Apr;19(4):541-5
pubmed: 22300792
J Mol Neurosci. 2014 Feb;52(2):250-60
pubmed: 24214103
Oncogene. 2012 Oct 4;31(40):4409-19
pubmed: 22249255
EMBO Mol Med. 2014 Oct 13;6(11):1359-70
pubmed: 25312641
Cancer Res. 2009 Jun 15;69(12):5251-8
pubmed: 19509227
Neuron. 2002 Dec 5;36(5):843-54
pubmed: 12467588
Genet Med. 2021 Nov;23(11):2138-2149
pubmed: 34244665
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
EMBO J. 1993 Jun;12(6):2249-56
pubmed: 8508762
Sci Rep. 2021 May 11;11(1):9964
pubmed: 33976246
Acta Neuropathol. 2020 Mar;139(3):603-608
pubmed: 31996992
Onco Targets Ther. 2018 Dec 04;11:8673-8684
pubmed: 30584325
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Clin Epigenetics. 2019 Jul 9;11(1):100
pubmed: 31288858